Bone health in neuroendocrine tumors and prognostic implications beyond skeletal metastases - Summary - MDSpire

Bone health in neuroendocrine tumors and prognostic implications beyond skeletal metastases

  • By

  • Andrea Casabella

  • Iderina Hasballa

  • Anna Arecco

  • Mara Boschetti

  • Leonardo Della Sala

  • Davide Demontis

  • Alberto Sulli

  • Lara Vera

  • Alessandro Veresani

  • Diego Ferone

  • Sabrina Paolino

  • Manuela Albertelli

  • July 1, 2026

  • 0 min

Share

Objective:

To assess the musculoskeletal status, its prognostic relevance and association with tumor aggressiveness in NET patients.

Approach:
  • Study Design: Cross-sectional study involving 41 patients with grade 1, 2, or 3 gastroenteropancreatic and lung NETs, compared with 47 healthy controls matched for age, sex, and BMI.
  • Assessment Method: Musculoskeletal health was assessed using dual-energy X-ray absorptiometry (DXA) scan.
Key Findings:
  • In the NET group, 71% had degraded trabecular bone score (TBS), 59% exhibited osteopenia at the femoral neck, 68% had hypovitaminosis D, and 37% showed low relative skeletal muscle index (RSMI) indicative of sarcopenia. Advanced-stage NETs correlated with lower bone mineral density (BMD) and vitamin D levels. Higher 25(OH)D levels and BMI were associated with longer progression-free survival (PFS).
Interpretation:

NET patients experience significant musculoskeletal impairment, with deterioration in trabecular microarchitecture evident despite normal BMD compared to healthy controls.

Limitations:
  • Small sample size of 41 patients limits generalizability.
  • Retrospective design may introduce bias.
Conclusion:

Findings require validation in larger prospective studies.

Original Source(s)

Related Content